Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process (2022 - 2025)

Axsome Therapeutics' Work In Process history spans 4 years, with the latest figure at $17.8 million for Q4 2025.

  • For Q4 2025, Work In Process rose 130.95% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, up 130.95%, while the annual FY2025 figure was $17.8 million, 130.95% up from the prior year.
  • Work In Process for Q4 2025 was $17.8 million at Axsome Therapeutics, up from $12.9 million in the prior quarter.
  • Across five years, Work In Process topped out at $17.8 million in Q4 2025 and bottomed at $6.8 million in Q1 2025.
  • The 4-year median for Work In Process is $10.4 million (2023), against an average of $10.6 million.
  • The largest YoY upside for Work In Process was 130.95% in 2025 against a maximum downside of 37.64% in 2025.
  • A 4-year view of Work In Process shows it stood at $14.0 million in 2022, then decreased by 26.34% to $10.3 million in 2023, then decreased by 24.92% to $7.7 million in 2024, then surged by 130.95% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Work In Process are $17.8 million (Q4 2025), $12.9 million (Q3 2025), and $7.5 million (Q2 2025).